445 related articles for article (PubMed ID: 33832346)
1. Fluoropyrimdine therapy induced alterations in interleukins expression in colorectal cancer patients.
Fouad MA; Salem SE; Osman AS; Badr DM; Hussein MM; Zekri AN; Hafez HF; Kamel MM; Shouman SA
Int J Immunopathol Pharmacol; 2021; 35():20587384211008332. PubMed ID: 33832346
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy.
Huang CW; Ma CJ; Su WC; Chen YT; Tsai HL; Yeh YS; Chang TK; Hsu WH; Yu FJ; Wang JY
Oncol Res; 2021 Sep; 28(7):701-714. PubMed ID: 32859280
[TBL] [Abstract][Full Text] [Related]
3. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
4. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
Varma A; Mathaiyan J; Shewade D; Dubashi B; Sunitha K
J Clin Pharm Ther; 2020 Aug; 45(4):617-627. PubMed ID: 32399998
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
6. Two variants of Interleukin-1B gene are associated with the decreased risk, clinical features, and better overall survival of colorectal cancer: a two-center case-control study.
Qian H; Zhang D; Bao C
Aging (Albany NY); 2018 Dec; 10(12):4084-4092. PubMed ID: 30563955
[TBL] [Abstract][Full Text] [Related]
7. Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial.
Tapia Rico G; Price T; Tebbutt N; Hardingham J; Lee C; Buizen L; Wilson K; Gebski V; Townsend A
Clin Colorectal Cancer; 2019 Jun; 18(2):141-148. PubMed ID: 30713134
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of serum interleukin-17 levels in colorectal cancer patients.
Karabulut S; Usul Afsar C; Karabulut M; Kilic L; Alis H; Kones O; Bilgin E; Faruk Aykan N
J BUON; 2016; 21(5):1137-1145. PubMed ID: 27837615
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma.
Konishi N; Miki C; Yoshida T; Tanaka K; Toiyama Y; Kusunoki M
Oncology; 2005; 68(2-3):138-45. PubMed ID: 16006751
[TBL] [Abstract][Full Text] [Related]
10. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
Hegewisch-Becker S; Nöpel-Dünnebacke S; Hinke A; Graeven U; Reinacher-Schick A; Hertel J; Lerchenmüller CA; Killing B; Depenbusch R; Al-Batran SE; Lange T; Dietrich G; Tannapfel A; Arnold D
Eur J Cancer; 2018 Sep; 101():105-113. PubMed ID: 30036739
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
12. Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients.
Sun J; Ilich AI; Kim CA; Chu MP; Wong GG; Ghosh S; Danilak M; Mulder KE; Spratlin JL; Chambers CR; Sawyer MB
Clin Colorectal Cancer; 2016 Sep; 15(3):257-63. PubMed ID: 26803708
[TBL] [Abstract][Full Text] [Related]
13. Effects of oxaliplatin on inflammation and intestinal floras in rats with colorectal cancer.
Luo H; Liu L; Zhao JJ; Mi XF; Wang QJ; Yu M
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10542-10549. PubMed ID: 33155210
[TBL] [Abstract][Full Text] [Related]
14. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
16. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
17. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and Diagnostic Values of miR-506 and SPON 1 in Colorectal Cancer with Clinicopathological Considerations.
Tamjidifar R; Akbari M; Tarzi S; Sadeghzadeh M; Abolghasemi M; Poursaei E; Shomali N; Mahdavi F
J Gastrointest Cancer; 2021 Mar; 52(1):125-129. PubMed ID: 31927744
[TBL] [Abstract][Full Text] [Related]
19. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
